These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10331407)

  • 1. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
    Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
    Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
    Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
    Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
    Park CW; Kim HW; Ko SH; Lim JH; Ryu GR; Chung HW; Han SW; Shin SJ; Bang BK; Breyer MD; Chang YS
    J Am Soc Nephrol; 2007 Apr; 18(4):1227-38. PubMed ID: 17360951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
    Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
    Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exendin-4(Lys
    Hasib A; Ng MT; Tanday N; Craig SL; Gault VA; Flatt PR; Irwin N
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3106. PubMed ID: 30499633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
    Szayna M; Doyle ME; Betkey JA; Holloway HW; Spencer RG; Greig NH; Egan JM
    Endocrinology; 2000 Jun; 141(6):1936-41. PubMed ID: 10830274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues.
    Pohl M; Wank SA
    J Biol Chem; 1998 Apr; 273(16):9778-84. PubMed ID: 9545315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
    Han J; Sun LD; Qian H; Huang WL
    Chin J Nat Med; 2014 Aug; 12(8):613-8. PubMed ID: 25156287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
    Wang Q; Brubaker PL
    Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
    Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
    Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
    Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
    J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
    Rolin B; Larsen MO; Gotfredsen CF; Deacon CF; Carr RD; Wilken M; Knudsen LB
    Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E745-52. PubMed ID: 12217892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice.
    Zhang B; Graziano MP; Doebber TW; Leibowitz MD; White-Carrington S; Szalkowski DM; Hey PJ; Wu M; Cullinan CA; Bailey P; Lollmann B; Frederich R; Flier JS; Strader CD; Smith RG
    J Biol Chem; 1996 Apr; 271(16):9455-9. PubMed ID: 8621615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.